88 related articles for article (PubMed ID: 7903550)
21. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
Witjes WP; Rosier PF; Caris CT; Debruyne FM; de la Rosette JJ
Urology; 1997 Feb; 49(2):197-205; discussion 205-6. PubMed ID: 9037281
[TBL] [Abstract][Full Text] [Related]
22. [Pressure and metabolic effects of terazosin in essential hypertension].
Valle R; Semplicini A; Serena L; Gebbin A; Fontebasso A; Gerardi G; De Toni R; Pessina AC
Cardiologia; 1994 Jun; 39(6):421-4. PubMed ID: 7923256
[TBL] [Abstract][Full Text] [Related]
23. Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms.
Lepor H; Theune C
J Urol; 1995 Jul; 154(1):116-8. PubMed ID: 7776406
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension.
Beretta-Piccoli C; Ferrier C; Weidmann P
J Hypertens Suppl; 1985 Dec; 3(3):S231-4. PubMed ID: 2908818
[TBL] [Abstract][Full Text] [Related]
26. Clinical experience: symptomatic management of BPH with terazosin.
Dunzendorfer U
Urology; 1988 Dec; 32(6 Suppl):27-31. PubMed ID: 2462302
[TBL] [Abstract][Full Text] [Related]
27. [Results of monotherapy with terazosin (kornam) in chronic infectious prostatitis patients].
Lopatkin NA; Apolikhin OI; Sivkov AV; Oshchepkov VN; Egorov AA
Urologiia; 2002; (5 Suppl):37-52. PubMed ID: 12518671
[TBL] [Abstract][Full Text] [Related]
28. Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents.
Louis WJ; McNeil JJ; Anavekar SN; Conway EL; Workman B; Howes LG; Drummer OH; Jarrott B
J Cardiovasc Pharmacol; 1987; 10 Suppl 12():S100-3. PubMed ID: 2455158
[TBL] [Abstract][Full Text] [Related]
29. Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia.
Dogra PN; Biswas NR; Ravi AK; Mani K; Kumar V
J Indian Med Assoc; 2005 Feb; 103(2):108-10, 112. PubMed ID: 16008322
[TBL] [Abstract][Full Text] [Related]
30. More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study.
Paick JS; Lee SC; Ku JH
Prostate Cancer Prostatic Dis; 2006; 9(3):261-5. PubMed ID: 16683008
[TBL] [Abstract][Full Text] [Related]
31. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
33. Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension.
Silke B; Guy S; Humphreys JE
J Hum Hypertens; 1992 Jun; 6(3):221-5. PubMed ID: 1352828
[TBL] [Abstract][Full Text] [Related]
34. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
Lepor H; Knapp-Maloney G; Wozniak-Petrofsky J
Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):392-7. PubMed ID: 2477339
[TBL] [Abstract][Full Text] [Related]
35. Combined use of melatonin and terazosin restores bladder contractility in rabbits with partial outlet obstruction.
Onur R; Tasdemir C; Seckin D; Ilhan N; Kutlu S; Akpolat N
Urology; 2008 Aug; 72(2):439-43. PubMed ID: 18455780
[TBL] [Abstract][Full Text] [Related]
36. Effect of age on the pharmacokinetics of orally and intravenously administered terazosin.
Sennello LT; Sonders RC; Glassman HN; Jordan DC; Luther RR; Tolman KG
Clin Ther; 1988; 10(5):600-7. PubMed ID: 2908805
[TBL] [Abstract][Full Text] [Related]
37. Terazosin for the treatment of trauma-related nightmares: a report of 4 cases.
Nirmalani-Gandhy A; Sanchez D; Catalano G
Clin Neuropharmacol; 2015; 38(3):109-11. PubMed ID: 25970279
[TBL] [Abstract][Full Text] [Related]
38. New-onset priapism associated with ingestion of terazosin in an otherwise healthy man.
Sadeghi-Nejad H; Jackson I
J Sex Med; 2007 Nov; 4(6):1766-8. PubMed ID: 17451488
[TBL] [Abstract][Full Text] [Related]
39. Clinical applications of alpha 1-receptor blockade: terazosin in the management of hypertension. Introduction.
Rosenthal J; Kyncl JJ
J Clin Pharmacol; 1993 Sep; 33(9):866-7. PubMed ID: 7901240
[No Abstract] [Full Text] [Related]
40. Re: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms.
Frankel G
J Urol; 1996 Mar; 155(3):1039. PubMed ID: 8583558
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
